Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers.
about
The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesisThe Severe Acute Respiratory Syndrome (SARS)-coronavirus 3a protein may function as a modulator of the trafficking properties of the spike proteinA Brief Review: The Z-curve Theory and its Application in Genome Analysis.The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death.Severe acute respiratory syndrome coronavirus 3a protein is released in membranous structures from 3a protein-expressing cells and infected cells.False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV.A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis.Characterization of a unique group-specific protein (U122) of the severe acute respiratory syndrome coronavirus.Rapid response research to emerging infectious diseases: lessons from SARS.Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoproteinVaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.SARS coronavirus accessory proteins.A rapid point of care immunoswab assay for SARS-CoV detection.Use of viral lysate antigen combined with recombinant protein in Western immunoblot assay as confirmatory test for serodiagnosis of severe acute respiratory syndrome.False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike pThe YXXΦ motif within the severe acute respiratory syndrome coronavirus (SARS-CoV) 3a protein is crucial for its intracellular transport.Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection.Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway.Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients.Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patientsDifferential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia.Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M.Naturally occurring anti-Escherichia coli protein antibodies in the sera of healthy humans cause analytical interference in a recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay for serodiagnosis of severe acute respiratory syndAmino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agentsInfluence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome.
P2860
Q24605877-54C9EF77-77BE-4FCB-B67C-10AF21867E6FQ24792382-B6E4C900-621F-421F-81D9-F6D1E9329242Q28239990-8A0BAA70-9C8B-4F23-934D-AEB2D7DB1637Q30492548-E4626F39-3BF3-4261-922D-C408A6A140EDQ34233067-2EC792BD-3C47-433B-9F0A-DA3CB51189FCQ34429423-C0A03E5B-FB5F-4296-8902-36D8385E4AEEQ34438872-8237B101-78E3-4CA7-B618-30232672894AQ35123004-AB98240E-B0BC-4373-BEBD-0DB97EB707C5Q35805407-4FEACD2E-F02C-4BC1-A209-ACA33BC54ABEQ35817398-4A6A20AB-76FA-43E0-B157-15D3BCA18A89Q36315168-713D5DBB-C031-4AC3-8221-CDAC5628895BQ36784740-0291EBE0-2C78-43EF-A224-D6EDB08FAF43Q37018286-BA21EC7E-8C40-4274-8B39-8ECC5C973600Q37184045-5E1C4EC0-9BA2-4EF5-95CB-35B4B2E44055Q37595195-453E072A-1771-4BDB-9B37-36EF1FD21D45Q37702502-BE50CD9B-3871-4C0D-BA91-8EEA80B88E21Q37732056-D2D853F7-36B6-4F05-A586-C9AFBF8CD327Q40041686-337CE095-0429-4412-A0DC-8939F92F5D6DQ40487857-E62BE3A0-6D1A-478C-A83D-A8BBF46D2D30Q40685865-E6863A5E-C15C-4993-9856-A6AF9BC41F49Q41814768-1EE9B07A-6CD8-4C4E-94FD-8ED6377B7ED8Q41828714-6BEEF1EB-32E7-4ABE-B9B2-DD217ACB1FB3Q41861879-480C323C-F295-4D0F-A1C7-AE585E00E65DQ41991682-1B7B2286-5FF1-4C6B-8CAC-B7437F78BFFAQ42716746-58E4709F-600E-4165-B89B-F7F5F46BC690Q47721502-2E3ACBF1-07A0-46EA-ADC8-147AFB3E7C4E
P2860
Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Profiles of antibody responses ...... ial use as diagnostic markers.
@en
Profiles of antibody responses ...... ial use as diagnostic markers.
@nl
type
label
Profiles of antibody responses ...... ial use as diagnostic markers.
@en
Profiles of antibody responses ...... ial use as diagnostic markers.
@nl
prefLabel
Profiles of antibody responses ...... ial use as diagnostic markers.
@en
Profiles of antibody responses ...... ial use as diagnostic markers.
@nl
P2093
P2860
P50
P1476
Profiles of antibody responses ...... ial use as diagnostic markers.
@en
P2093
Ai Ee Ling
Chih-Fong Chou
Hoe Nam Leong
Jian-Lin Fu
Phuay-Yee Goh
Seng Gee Lim
Wanjin Hong
P2860
P304
P356
10.1128/CDLI.11.2.362-371.2004
P577
2004-03-01T00:00:00Z